^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    icosapent ethyl

    i
    Other names: AMR 101, LAX 101, ethyl eicosapentaenoate, ethyl icopenate, ethyl-EPA, icosapent ethyl, icosapentaenoic acid ethyl ester, LAX 101c, ultra-pure eicosapentaenoic acid, ultra-pure EPA, LAX101, AMR101, MND-21, EPA-E
    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    PLA2 inhibitor, Caspase inhibitor, DGAT inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    SALVAGE: IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    icosapent ethyl
    9ms
    ARTCAP: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (clinicaltrials.gov)
    P4, N=0, Withdrawn, University of Louisville | N=200 --> 0 | Trial completion date: Jan 2029 --> Jan 2025 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2029 --> Jan 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    icosapent ethyl
    10ms
    Acquired Generalized Lipodystrophy as an Adverse Event of Combined Immune Checkpoint Inhibitor Therapy. (PubMed, JCEM Case Rep)
    We present a 48-year-old female with recurrent malignant melanoma who underwent 23 cycles of nivolumab, a PD-1 inhibitor, and 11 cycles of combined cytotoxic T lymphocyte associated antigen 4 (CTLA-4) inhibitor and PD-1 inhibitor ipilimumab-nivolumab. Treatment included insulin (average total daily dose 0.13-0.26 Units/kg/day) and a combination of lipid-lowering therapy (statins, fenofibrate, icosapent ethyl), which led to marked improvement in triglycerides and symptoms. This case further underscores the emerging challenges with endocrinopathies associated with checkpoint inhibitors.
    Journal • Adverse events • Checkpoint inhibition
    |
    LEP (Leptin)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • icosapent ethyl
    12ms
    Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk in Patients Undergoing Secondary Prevention for Cardiovascular Disease. (clinicaltrials.gov)
    P=N/A, N=294, Not yet recruiting, University of Sao Paulo
    New trial
    |
    CRP (C-reactive protein)
    |
    icosapent ethyl
    1year
    Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases (clinicaltrials.gov)
    P=N/A, N=81, Completed, University of Leeds | Recruiting --> Completed | N=250 --> 81 | Trial completion date: Jul 2025 --> Jul 2024
    Trial completion • Enrollment change • Trial completion date
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCL2 (Chemokine (C-C motif) ligand 2)
    |
    icosapent ethyl
    over1year
    Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia (clinicaltrials.gov)
    P3, N=316, Completed, Mochida Pharmaceutical Company, Ltd. | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Dec 2023 --> Jul 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    icosapent ethyl
    over1year
    Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation. (PubMed, J Am Heart Assoc)
    These direct actions of EPA on EC functions during inflammation may contribute to its distinct cardiovascular benefits.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • ICAM1 (Intercellular adhesion molecule 1)
    |
    icosapent ethyl
    over1year
    The sphingosine-1-phosphate receptor 1 mediates the atheroprotective effect of eicosapentaenoic acid. (PubMed, Nat Metab)
    Finally, we show that Vascepa, a prescription drug containing highly purified and stable EPA ethyl ester, exerts its cardiovascular protective effect through the 17,18-EEQ-S1PR1 pathway in male and female mice. Collectively, our findings indicate that the anti-inflammatory effect of 17,18-EEQ involves the activation of the S1PR1-Gq-Ca2+-eNOS axis in ECs, offering a potential therapeutic target against atherosclerosis.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • NOS3 (Nitric oxide synthase 3) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    |
    icosapent ethyl
    over1year
    SALVAGE: IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion (clinicaltrials.gov)
    P2, N=110, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    New P2 trial
    |
    icosapent ethyl
    over1year
    IPE-PREVENTION: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk (clinicaltrials.gov)
    P4, N=70, Completed, Canadian Medical and Surgical Knowledge Translation Research Group | Active, not recruiting --> Completed
    Trial completion
    |
    CRP (C-reactive protein)
    |
    icosapent ethyl
    over1year
    ARTCAP: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (clinicaltrials.gov)
    P4, N=200, Recruiting, University of Louisville | Not yet recruiting --> Recruiting
    Enrollment open
    |
    icosapent ethyl
    almost2years
    ARTCAP: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (clinicaltrials.gov)
    P4, N=200, Not yet recruiting, University of Louisville
    New P4 trial
    |
    icosapent ethyl